Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was ...

Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

10x Genomics, Inc. (NASDAQ:TXG) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It has announced a global settlement agreement with Bruker Corporation, which resolves all ...

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems.

As per the agreement, from Q3 2025 to Q2 2026, Bruker will pay 10x Genomics, Inc. (NASDAQ:TXG) $68 million in equal quarterly installments.

Revenue Growth: Over the 3M period, 10x Genomics showcased positive performance, achieving a revenue growth rate of 9.84% as of 31 March, 2025. This reflects a substantial increase in the company ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at life sciences tools & services ...

Review the current valuation for 10x Genomics Inc Ordinary Shares - Class A (TXG:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Review 10x Genomics Inc Ordinary Shares - Class A (TXG:XNAS) stock and the current sustainability and ESG risk rating to help with your investing decisions.